|
Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences
|
|
CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines
|
|
Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6
|
|
Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells
|
|
Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma
|
|
Immunotherapeutic strategies for the treatment of plasma cell malignancies
|
|
Isolation and characterization of human multiple myeloma cell enriched populations
|
|
Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis
|
|
Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage
|
|
Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone
|
|
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
|
|
The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders
|
|
Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens
|
|
Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy
|
